The European Medicines Agency (EMA) is recommending the use of Gilead Sciences’ (GILD +1.4%) remdesivir for treating COVID-19 in compassionate use programs.
EMA advisory group CHMP is encouraging the company
to make the antiviral available in a “fair and transparent” way to
member states wishing to participate in international clinical trials or
treating patients under compassionate use.
https://seekingalpha.com/news/3558339-gileads-remdesivir-okd-in-europe-for-compassionate-use-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.